27457 Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over 36 months of treatment: PURE study - 07/08/21
Doi : 10.1016/j.jaad.2021.06.593
Melinda Gooderham, MD
SKiN Center for Dermatology and Probity Medical Research, Peterborough, and Queen’s University, Kingston, ON, Canada
Michael Robern, MD
Dermatology Ottawa Research Centre and Probity Medical Research, Ottawa, Ontario, Canada
Dusan Sajic, MD, PhD
Derma Skin Institute and Probity Medical Research
Assistant Professor Clinical Medicine (Adjunct), Department of Medicine, McMaster University, Guelph, ON, Canada
Carmen Taveras
Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago de los Caballeros, Dominican Republic
Il testo completo di questo articolo è disponibile in PDF.
| Commercial Disclosure: This investigation was sponsored by Novartis Pharmaceuticals Canada Inc. Editorial and medical writing support was funded by Novartis Pharmaceuticals Canada Inc, in accordance with GPP3 guidelines. |
© 2021
Pubblicato da Elsevier Masson SAS.
Vol 85 - N° 3S
P. AB145 - settembre 2021 Ritorno al numero
Articolo precedente
- 27454 Efficacy and safety of long-term risankizumab re-treatment following drug withdrawal: IMMhance trial
- Richard G. Langley, Stephen K. Tyring, Atsuyuki Igarashi, Sandra Philipp, Jiewei Zeng, Christian Kaufmann, Andrew Blauvelt
- 27459 Protection potential of echinochrome A on UV damaged skin
- Seong Min Hong, Sang Woo Ahn, Jong Uk Kim, Gyeong Je Cho, Woo Jung Jin, So Hee Park, Jin Han, Hyojin Kim, Jung Eun Seol
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?